Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: From experimental models to human trials

Jeremy Ben-Shoshan, Jacob George*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations

Abstract

Cell-based therapy approaches for the restoration of blood flow in ischemic organs has recently received growing interest. A considerable number of reports have documented the presence of circulating, bone marrow-derived endothelial progenitor cells (EPC) in adult peripheral blood. These putative cells are thought to participate in postnatal growth of new blood vessels. Mounting evidence from animal studies point to potential therapeutic applications of EPCs in the treatment of a wide range of cardiovascular (CV) disorders, while preliminary results from the pilot clinical trials still remain equivocal. Here, we review the experimental data that has accumulated so far from animal and clinical studies regarding the potential importance of EPCs. In addition, we discuss the potential hurdles as well as future options of EPC-based therapy.

Original languageEnglish
Pages (from-to)25-36
Number of pages12
JournalPharmacology and Therapeutics
Volume115
Issue number1
DOIs
StatePublished - Jul 2007

Keywords

  • Bone marrow
  • Cardiovascular diseases
  • Cell-based therapy
  • Endothelial progenitor cells
  • Mobilization
  • Peripheral blood

Fingerprint

Dive into the research topics of 'Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: From experimental models to human trials'. Together they form a unique fingerprint.

Cite this